Meshconomy

Pulsight

Wearable medical patch assessing vital signs during trauma

Israel

1-10

Vitality Radar

Current

6M History

Industry

Updated 1 day ago

Pillar Analysis

Presence

Digital footprint, brand visibility, and online reach across channels

Business

Revenue signals, funding status, partnerships, and market traction

Innovation

R&D activity, patents, product launches, and technology adoption

Pulse

Recent momentum — hiring trends, news mentions, and social engagement

Capacity

Team strength, leadership depth, and organizational scale

Strategic Assessment

Strategic Vector

PulseSight Therapeutics is advancing clinical-stage non-viral gene therapies for retinal diseases like dry and wet AMD, with a Phase I trial for lead candidate PST-611 starting Q2 2025 and Series A funding secured to support progression to Phase II.

Efficiency Ratio

Early-stage biotech demonstrates strong innovation-to-funding efficiency with recent Series A close enabling imminent clinical milestones despite limited organizational scale.

Evidence Signals

Product Launch HIGH Paris, France

Phase I clinical trial (PST-611-CT1) for PST-611 targeting dry AMD and geographic atrophy scheduled to commence in early Q2 2025, with results expected late 2025 or early 2026.

View source

Funding HIGH Paris, France

Announced first close of Series A financing round in February 2025, with Pureos BioVentures committing new funds to support Phase I of PST-611 and Phase IIa preparation.

View source

Partnership HIGH Paris, France

Portfolio investment by SPRIM Global Investments in PulseSight Therapeutics, an ophthalmology drug development company.

View source

Expansion HIGH Paris, France

Development of second program PST-809 for wet AMD, with preclinical studies showing superior efficacy to current treatments via dual-gene plasmid therapy.

View source

Leadership Change MEDIUM Paris, France

Judith Greciet listed as CEO of PulseSight Therapeutics.

View source

Other HIGH Paris, France

Company founded in 2024 as a clinical-stage biotech specializing in non-viral vectorized therapies with proprietary electro-transfection delivery system.

View source

About: Pulsight develops an innovative, wearable neck patch that rapidly assesses vital signs for trauma victims. The device assists military medics in prioritizing care during mass-casualty events on the battlefield by quickly triaging patients and enabling faster life-saving treatments.
Tags

Suggest an edit